Analyses of Activity for Factor Xa Inhibitors Based on Monte Carlo Simulations

Journal of Medicinal Chemistry

Volumn 46, Issue 26, 2003, Pages 5691-5699

  Ostrovsky, Dennis ^a   Udier Blagović, Marina ^a   Jorgensen, William L ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; WATER;

ANALYTICAL ERROR; ARTICLE; CALCULATION; COMPUTER SIMULATION; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; MONTE CARLO METHOD; PHYSICAL CHEMISTRY; STRUCTURE ANALYSIS;

BINDING SITES; FACTOR XA; HUMANS; HYDROGEN BONDING; LIGANDS; MODELS, MOLECULAR; MONTE CARLO METHOD; PROTEASE INHIBITORS; PYRIDINES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REGRESSION ANALYSIS; THERMODYNAMICS;

EID: 0346996360     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030288d     Document Type: Article

References (42)

1. Davie, E. W.; Fujikawa, K.; Kisiel, W. The coagulation cascade: Initiation, maintenance, and regulation. Biochemistry 1991, 30, 10363-70.
2. Vlasuk, G. P. Direct Factor Xa Inhibitors. In New Therapeutic Agents in Thrombosis and Thrombolysis, 1st ed.; Sasahara, A. A., Loscalzo, J., Ed.; Marcel Dekker: New York, 1997.
3. Kaiser, B. Factor Xa - A promising target for drug development. Cell. Mol. Life Sci. 2002, 59, 189-192.
4. Mann, K. G.; Nesheim, M. E.; Church, W. R.; Haley, P.; Krishnaswamy, S. Surface Dependent Reactions of the Vitamin K-Dependent Enzyme Complexes. Blood 1990, 76, 1-16.
5. Prasa, D.; Svendsen, L.; Sturzebecher, J. Inhibition of thrombin generation in plasma by inhibitors of factor Xa. Thromb. Haemost. 1997, 78, 1215-1220.
6. Pierce, A. C.; Jorgensen, W. L. Estimation of Binding Affinities for Selective Thrombin Inhibitors via Monte Carlo Simulations. J. Med. Chem. 2001, 44, 1043-50.
7. Wesolowski, S. S.; Jorgensen, W. L. Estimation of binding affinities for celecoxib analogues with COX-2 via Monte Carlo-extended linear response. Bioorg. Med. Chem. Lett. 2002, 12, 267-70.
8. Rizzo, R. C.; Tirado-Rives, J.; Jorgensen, W. L. Estimation of Binding Affinities for HEPT and Nevirapine Analogues with HIV-1 Reverse Transcriptase via Monte Carlo Simulations. J. Med. Chem. 2001, 44, 145-154.
9. Rizzo, R. C.; Udier-Blagović, M.; Wang, D.; Watkins, E. K.; Smith, M. B. K.; Smith, R. H. J.; Tirado-Rives, J.; Jorgensen, W. L. Prediction of Activity for Nonnucleoside Inhibitors with HIV-1 Reverse Transcriptase Based on Monte Carlo Simulations. J. Med. Chem. 2002, 45, 2970-87.
10. Phillips, G.; Davey, D. D.; Eagen, K. A.; Koovakkat, S. K.; Liang, A.; Ng, H. P.; Pinkerton, M.; Trinh, L.; Whitlow, M.; Beatty, A. M.; Morrissey, M. M. Design, synthesis, and activity of 2,6-diphenoxypyridine-derived factor Xa inhibitors. J. Med. Chem. 1999, 42, 1749-1756.
11. Phillips, G.; Guilford, W. J.; Buckman, B. O.; Davey, D. D.; Eagen, K. A.; Koovakkat, S.; Liang, A.; McCarrick, M.; Mohan, R.; Ng, H. P.; Pinkerton, M.; Subramanyam, B.; Ho, E.; Trinh, L.; Whitlow, M.; Wu, S.; Xu, W.; Morrissey, M. M. Design, synthesis, and activity of a novel series of factor Xa inhibitors: Optimization of arylamidine groups. J. Med. Chem. 2002, 45, 2484-2493.
12. Jorgensen, W. L. Free Energy Changes in Solution. In Encyclopedia of Computational Chemistry; Schleyer, P. v. R., Ed.; Wiley: New York, 1998; Vol. 2, pp 1061-1070.
13. Lamb, M. L.; Jorgensen, W. L. Computational approaches to molecular recognition. Curr. Opin. Chem. Biol. 1997, 1, 449-457.
14. Kollman, P. Free Energy Calculations: Applications to Chemical and Biochemical Phenomena. Chem. Rev. 1993, 93, 2395-2417.
15. Jorgensen, W. L. Free Energy Calculations: A Breakthrough For Modeling Organic Chemistry in Solution. Acc. Chem. Res. 1989, 22, 184-189.
16. Åqvist, J.; Medina, C.; Samuelsson, J.-E. A New Method For Predicting Binding Affinity in Computer-Aided Drug Design. Protein Eng. 1994, 7, 385-391.
17. (a) Carlson, H. A.; Jorgensen, W. L. An Extended Linear Response Method For Determining Free Energies of Hydration. J. Phys. Chem. 1995, 99, 10667-10673.
18. (b) McDonald, N. A.; Carlson, H. A.; Jorgensen, W. L. Free energies of solvation in chloroform and water from a linear response approach. J. Phys. Org. Chem. 1997, 10, 563-576.
19. Hansson, T.; Åqvist, J. Estimation of binding free energies for HIV proteinase inhibitors by molecular dynamics simulations. Protein Eng. 1995, 8, 1137-1144.
20. Paulsen, M. D.; Ornstein, R. L. Binding free energy calculations for P450cam-substrate complexes. Protein Eng. 1996, 9, 567-571.
21. Hulten, J.; Bonham, N. M.; Nillroth, U.; Hansson, T.; Zuccarello, G.; Bouzide, A.; Aqvist, J.; Classon, B.; Danielson, U. H.; Karlen, A.; Kvarnstrom, I.; Samuelsson, B.; Hallberg, A. Cyclic HIV-1 Protease Inhibitors Derived from Mannitol: Synthesis, Inhibitory Potencies, and Computational Predictions of Binding Affinities. J. Med. Chem. 1997, 40, 885-897.
22. Hansson, T.; Marelius, J.; Aqvist, J. Ligand binding affinity prediction by linear interaction energy methods. J. Comput.-Aided Mol. Des. 1998, 12, 27-35.
23. Wang, W.; Wang, J.; Kollman, P. A. What Determines the van der Waals Coefficient beta in the LIE (Linear Interaction Energy) Method to Estimate Binding Free Energies Using Molecular Dynamics Simulations? Proteins 1999, 34, 395-402.
24. Jones-Hertzog, D. K.; Jorgensen, W. L. Binding affinities for Sulfonamide Inhibitors with human Thrombin Using Monte Carlo Simulations with a Linear Response Methodol. J. Med. Chem. 1997, 40, 1539-49.
25. Smith, R. H.; Jorgensen, W. L.; Tirado-Rives, J.; Lamb, M. L.; Janssen, P. A. J.; Michejda, C. J.; Smith, M. B. K. Prediction of Binding Affinities for TIBO Inhibitors of HIV-1 Reverse Transcriptase Using Monte Carlo Simulations in a Linear Response Methodol. J. Med. Chem. 1998, 41, 1, 5272-5286.
26. Lamb, M. L.; Tirado-Rives, J.; Jorgensen, W. L. Estimation of the binding affinities of FKBP12 inhibitors using a linear response method. Bioorg. Med. Chem. 1999, 7, 851-860.
27. Duffy, E. M.; Jorgensen, W. L. Prediction of Properties from Simulations: Free Energies of Solvation in hexadecane, Octanol and Water. J. Am. Chem. Soc. 2000, 122, 2878-2888.
28. Udier-Blagović, M.; Watkins, E. K.; Tirado-Rives, J.; Jorgensen, W. L. Activity Predictions for Efavirenz Analogues with the K103N Mutant of HIV Reverse Transcriptase. Bioorg. Med. Chem. Lett. 2003, 13, 3337-3340.
29. Adler, M.; Davey, D. D.; Phillips, G. B.; Kim, S. H.; Jancarik, J.; Rumennik, G.; Light, D. R.; Whitlow, M. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry 2000, 39, 12534-12542.
30. Tirado-Rives, J. CHOP, Version 1.0; Yale University: New Haven, CT, 2001.
31. Tirado-Rives, J. PEPZ, Version 1.0; Yale University: New Haven, CT, 1997.
32. Jorgensen, W. L. GenMol, Version 2.2; Yale University: New Haven, CT, 2003.
33. Storer, J. W.; Giesen, D. J.; Cramer, C. J.; Truhlar, D. G. Class-Iv Charge Models - A New Semiempirical Approach in Quantum-Chemistry. J. Comput.-Aided Mol. Des. 1995, 9, 87-110.
34. Jorgensen, W. L.; Maxwell, D. S.; Tirado-Rives, J. Development and Testing of the OPLS All-Atom Force Field on Conformational Energetics and Properties of Organic Liquids. J. Am. Chem. Soc. 1996, 118, 11225-11236.
35. Jorgensen, W. L.; Chandrasekhar, J.; Madura, J. D.; Impey, R. W.; Klein, M. L. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983, 79, 926-935.
36. Jorgensen, W. L. MCPRO, Version 1.67; Yale University: New Haven, Connecticut, 2001.
37. Rizzo, R. C.; Wang, D.; Tirado-Rives, J.; Jorgensen, W. L. Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Sustiva through Computation of Resistance Profiles. J. Am. Chem. Soc. 2000, 122, 12898-12900.
38. Udier-Blagović, M.; Tirado-Rives, J.; Jorgensen, W. L. Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Nonnucleoside Inhibitor TMC 125. J. Am. Chem. Soc. 2003, 125, 6016-6017.
39. JMP, Version 4; SAS Institute Inc., Cary, NC, 2000.
40. Padmanabhan, K.; Padmanabhan, K. P.; Tulinsky, A.; Park, C. H.; Bode, W. ; Huber, R.; Blankenship, D. T.; Cardin, A. D.; Kisiel, W. Structure of human des(1-45) factor Xa at 2.2 A resolution. J. Mol. Biol. 1993, 232, 947-966.
41. Herron, D. K.; Goodson, T., Jr.; Wiley, M. R.; Weir, L. C.; Kyle, J. A.; Yee, Y. K.; Tebbe, A. L.; Tinsley, J. M.; Mendel, D.; Masters, J. J.; Franciskovich, J. B.; Sawyer, J. S.; Beight, D. W.; Ratz, A. M.; Milot, G.; Hall, S. E.; Klimkowski, V. J.; Wikel, J. H.; Eastwood, B. J.; Towner, R. D.; Gifford-Moore, D. S.; Craft, T. J.; Smith, G. F. 1,2-Dibenzamidobenzene inhibitors of human factor Xa. J. Med. Chem. 2000, 43, 859-872.
42. Verner, E.; Katz, B. A.; Spencer, J. R.; Allen, D.; Hataye, J.; Hruzewicz, W.; Hui, H. C.; Kolesnikov, A.; Li, Y.; Luong, C.; Martelli, A.; Radika, K.; Rai, R.; She, M.; Shrader, W.; Sprengeler, P. A.; Trapp, S.; Wang, J.; Young, W. B.; Mackman, R. L. Development of serine protease inhibitors displaying a multicentered short (<2.3 Å) hydrogen bond binding mode: Inhibitors of urokinase-type plasminogen activator and factor Xa. J. Med. Chem. 2001, 44, 2753-2771.